Hepatitis B virus (HBV) infection is highly endemic in Senegal. Vaccination of all children against HBV was introduced 1999 and included Expanded Programme on Immunisation 2005. The aim this study to assess the prevalence immune status patients received at Pasteur Institut Dakar, Methods: Between January 2016 December 2020, aged between 1 96 years laboratory were study. Serum samples analysed f...

A novel miniature cell biosensor detection system for the detection of Hepatis B virus (HBV)-associated antigens and anti-HBV is described. The biosensor is based on "membrane-engineered" Vero fibroblast cells immobilized in an alginate matrix. The membrane-engineering process involved the electroinsertion of anti-HBV specific antibodies (anti-HBs, anti-HBe) or antigens (HBsAg) in the membranes...

Background: The antibody response to hepatitis B surface antigen (HBsAg) controls hepatitis B virus infection. The "a" determinant of HBsAg is the most important target for protective antibody response, diagnosis and immunoprophylaxis. Mutations in this area may induce immune escape mutants and affect the performance of HBsAg assays. Objectives: To construct clinically relevant recombinant muta...

BACKGROUND The coexistence of hepatitis B surface antigen (HBsAg) and antibodies to HBsAg (anti-HBs) in patients with chronic hepatitis B virus (HBV) infection has been explained by the presence of viral escape mutants. Yet, no systematic analysis of such patients has been performed. We analyzed both the HBV strains and the nature of anti-HBs in such patients. METHODS Four hundred eleven pati...

A case of fulminant viral hepatitis type B in the late stage of pregnancy was successfully treated with glucagon-insulin therapy, corticosteroids and other drugs. A 26-year-old female (housewife and primipara) suddenly developed severe hepatic dysfunction and disturbance of consciousness at the 36th week of pregnancy. Sequential blood examinations revealed early response to HBs antibody and del...

BACKGROUND AND AIM The best strategy for managing patients with resolved hepatitis B virus infection (HBsAg negative, anti-HBc antibodies positive with or without anti-HBs antibodies) and hematological malignancies under immunosuppressive therapies has not been defined. The aim of this study was to prospectively analyze the risk of hepatitis B virus reactivation in these patients. MATERIAL AN...

BACKGROUND Vaccination with the hepatitis B surface antigen (HBsAg) induces protective levels of antibody (anti-HBs = 10 IU/L) in majority of vaccinees. It has been shown that the levels of anti-HBs antibody do wane after vaccination. The aim of this study was to evaluate the persistence of anti-HBs antibodies in healthy Iranian children at 10 years after primary vaccination and the response to...

Hepatitis B surface antigen (HBsAg) and antibodies to both the surface and core antigens of the hepatitis B virus (anti-HBs and anti-HBc) have been studied in 64 consecutive cases of fulminant hepatitis. HBsAg was detected by counterelectrophoresis in 23 (35-9 %) but by radioimmunoassay in 38 (59-3 %). Anti-HBs was detected by passive haemagglutination in 26 (40-6 %), coexisting HBsAg and anti-...

AIM To explore the role of killer immunoglobulin receptor (KIR) genes in responsiveness or non-responsiveness to vaccination against hepatitis B virus. METHODS We recruited 101 voluntary participants between March 2010 and December 2011. Sera samples from vaccinated and non-vaccinated participants were tested for the presence of anti-HBs antibodies as a measure of protection against hepatitis...